Published in AIDS on October 23, 2016
A simple noninvasive index can predict both significant fibrosis and cirrhosis in patients with chronic hepatitis C. Hepatology (2003) 16.40
The Women's Interagency HIV Study. WIHS Collaborative Study Group. Epidemiology (1998) 12.32
Mechanisms of hepatic fibrogenesis. Gastroenterology (2008) 11.98
Development of a simple noninvasive index to predict significant fibrosis in patients with HIV/HCV coinfection. Hepatology (2006) 10.18
Epidemiology of viral hepatitis and HIV co-infection. J Hepatol (2005) 6.41
Clinical progression, survival, and immune recovery during antiretroviral therapy in patients with HIV-1 and hepatitis C virus coinfection: the Swiss HIV Cohort Study. Lancet (2000) 5.49
Obesity, abdominal obesity, physical activity, and caloric intake in US adults: 1988 to 2010. Am J Med (2014) 5.10
Lipids, lipoproteins, triglyceride clearance, and cytokines in human immunodeficiency virus infection and the acquired immunodeficiency syndrome. J Clin Endocrinol Metab (1992) 4.25
Muscle wasting is associated with mortality in patients with cirrhosis. Clin Gastroenterol Hepatol (2011) 3.64
The Multicenter AIDS Cohort Study: retention after 9 1/2 years. Am J Epidemiol (1995) 3.54
Mid-arm muscle circumference and quality of life and survival in maintenance hemodialysis patients. Clin J Am Soc Nephrol (2010) 2.68
Epidemiology, trends, and morbidities of obesity and the metabolic syndrome. Endocrine (2006) 2.61
Interactions of nutrition and infection. Monogr Ser World Health Organ (1968) 2.46
Sarcopenia, dynapenia, and the impact of advancing age on human skeletal muscle size and strength; a quantitative review. Front Physiol (2012) 2.37
Missing Data: How to Best Account for What Is Not Known. JAMA (2015) 2.36
Slower fibrosis progression in HIV/HCV-coinfected patients with successful HIV suppression using antiretroviral therapy. J Hepatol (2005) 2.27
Nutrition and HIV infection: review of weight loss and wasting in the era of highly active antiretroviral therapy from the nutrition for healthy living cohort. Clin Infect Dis (2006) 2.16
Guidelines for the use of antiretroviral agents in HIV-infected adults and adolescents. Department of Health and Human Services and Henry J. Kaiser Family Foundation. MMWR Recomm Rep (1998) 2.06
Hepatitis C virus hijacks host lipid metabolism. Trends Endocrinol Metab (2009) 2.05
Muscle wasting in disease: molecular mechanisms and promising therapies. Nat Rev Drug Discov (2015) 1.90
Hepatic decompensation in antiretroviral-treated patients co-infected with HIV and hepatitis C virus compared with hepatitis C virus-monoinfected patients: a cohort study. Ann Intern Med (2014) 1.64
The secular trend in human physical growth: a biological view. Econ Hum Biol (2003) 1.64
Nutritional status and mortality among HIV-infected patients receiving antiretroviral therapy in Tanzania. J Infect Dis (2011) 1.63
Nutrition and survival in patients with liver cirrhosis. Nutrition (2001) 1.60
Review of muscle wasting associated with chronic kidney disease. Am J Clin Nutr (2010) 1.55
The epidemiology of acute and chronic hepatitis C. Clin Liver Dis (1997) 1.36
Infection with the human immunodeficiency virus: clinical manifestations and their relationship to immune deficiency. A report from the Multicenter AIDS Cohort Study. Ann Intern Med (1987) 1.33
Malnutrition and wasting, immunodepression, and chronic inflammation as independent predictors of survival in HIV-infected patients. Nutrition (1999) 1.28
Clinical predictors for death in HIV-positive and HIV-negative tuberculosis patients in Guinea-Bissau. Infection (2007) 1.23
Cancer cachexia--pathophysiology and management. J Gastroenterol (2013) 1.20
Plasma amino-acid patterns in liver disease. Gut (1982) 1.19
Decreased limb muscle and increased central adiposity are associated with 5-year all-cause mortality in HIV infection. AIDS (2011) 1.19
Systematic review of antiretroviral-associated lipodystrophy: lipoatrophy, but not central fat gain, is an antiretroviral adverse drug reaction. PLoS One (2013) 1.16
Malnutrition in alcoholic and virus-related cirrhosis. Am J Clin Nutr (1996) 1.16
Glucose homeostasis in viral hepatitis. N Engl J Med (1970) 1.15
Contribution of nucleoside-analogue reverse transcriptase inhibitor therapy to lipoatrophy from the population to the cellular level. Antivir Ther (2003) 1.11
Cardiovascular disease in HIV infection. Curr Opin HIV AIDS (2011) 1.08
Functional impairment is associated with low bone and muscle mass among persons aging with HIV infection. J Acquir Immune Defic Syndr (2013) 1.07
Nutritional support in patients with chronic liver disease. Nat Clin Pract Gastroenterol Hepatol (2006) 1.06
Hepatitis B virus X protein upregulates oncogene Rab18 to result in the dysregulation of lipogenesis and proliferation of hepatoma cells. Carcinogenesis (2013) 1.04
Utility of standard nutritional parameters in detecting body cell mass depletion in patients with end-stage liver disease. Liver Transpl (2000) 1.02
Muscle wasting from kidney failure-a model for catabolic conditions. Int J Biochem Cell Biol (2013) 1.00
Assessment of simple risk markers for early mortality among HIV-infected patients in Guinea-Bissau: a cohort study. BMJ Open (2012) 0.97
Role of micronutrients in HIV-infected intravenous drug users. J Acquir Immune Defic Syndr (2000) 0.94
Altered fat distribution in HIV-positive men on nucleoside analog reverse transcriptase inhibitor therapy. J Acquir Immune Defic Syndr (2001) 0.92
The predictive value of anthropometric parameters on mortality in haemodialysis patients. Nephrol Dial Transplant (2010) 0.91
Dietary intake of community-based HIV-1 seropositive and seronegative injecting drug users. Nutrition (1997) 0.88
Very early anthropometric changes after antiretroviral therapy predict subsequent survival, in karonga, Malawi. Open AIDS J (2012) 0.87
Substance abuse, HIV-1 and hepatitis. Curr HIV Res (2012) 0.85
Hepatitis C infection and nonalcoholic fatty liver disease. Clin Liver Dis (2008) 0.83
Malnutrition in cirrhotic patients: anthropometric measurements as a method of assessing nutritional status. Br J Clin Pract (1990) 0.83
Nutrition issues in the HIV-infected injection drug user: findings from the nutrition for healthy living cohort. J Am Coll Nutr (2010) 0.81
Muscle and mortality in cirrhosis. Clin Gastroenterol Hepatol (2011) 0.80
Associations between changes in anthropometric measures and mortality in old age: a role for mid-upper arm circumference? J Am Med Dir Assoc (2012) 0.80
High prevalence of low skeletal muscle mass associated with male gender in midlife and older HIV-infected persons despite CD4 cell reconstitution and viral suppression. J Int Assoc Provid AIDS Care (2013) 0.80
Energy expenditure and protein metabolism in human immunodeficiency virus infection and cancer cachexia. Semin Oncol (1998) 0.80
Resting energy expenditure and substrate metabolism in Chinese patients with acute or chronic hepatitis B or liver cirrhosis. Intern Med (2010) 0.79
Assessment of nutritional status of patients with hepatitis C virus-related liver cirrhosis. Hepatol Res (2007) 0.79
Steatosis, insulin resistance and fibrosis progression in chronic hepatitis C. Minerva Gastroenterol Dietol (2006) 0.78
Basic data on anthropometric measurements and angular measurements of the hip and knee joints for selected age groups 1-74 years of age. Vital Health Stat 11 (1981) 0.78
Nutrition status predicts survival in cirrhosis. Nutr Rev (1996) 0.78
The energetics of wasting diseases. Curr Opin Clin Nutr Metab Care (2007) 0.77
Association between chronic hepatitis C virus infection and low muscle mass in US adults. J Viral Hepat (2014) 0.76
Nutritional support treatment for severe chronic hepatitis and posthepatitic cirrhosis. J Huazhong Univ Sci Technolog Med Sci (2006) 0.76
Nutritional status in patients with hepatitis C. J Coll Physicians Surg Pak (2012) 0.76
Chimeric antigen receptor T cells for sustained remissions in leukemia. N Engl J Med (2014) 8.21
Linezolid for treatment of chronic extensively drug-resistant tuberculosis. N Engl J Med (2012) 5.87
Use of recovery biomarkers to calibrate nutrient consumption self-reports in the Women's Health Initiative. Am J Epidemiol (2008) 4.28
Pegylated Interferon alfa-2a monotherapy results in suppression of HIV type 1 replication and decreased cell-associated HIV DNA integration. J Infect Dis (2012) 4.24
Comparison of predictive equations for resting metabolic rate in healthy nonobese and obese adults: a systematic review. J Am Diet Assoc (2005) 4.21
Nontuberculous mycobacterial lung disease prevalence at four integrated health care delivery systems. Am J Respir Crit Care Med (2010) 3.83
Low CD4+ T-cell count as a major atherosclerosis risk factor in HIV-infected women and men. AIDS (2008) 3.66
Fracture prevalence among human immunodeficiency virus (HIV)-infected versus non-HIV-infected patients in a large U.S. healthcare system. J Clin Endocrinol Metab (2008) 3.64
Efficacy and tolerability of 3 nonnucleoside reverse transcriptase inhibitor-sparing antiretroviral regimens for treatment-naive volunteers infected with HIV-1: a randomized, controlled equivalence trial. Ann Intern Med (2014) 3.48
Comparative effectiveness and safety of methods of insulin delivery and glucose monitoring for diabetes mellitus: a systematic review and meta-analysis. Ann Intern Med (2012) 3.47
A.S.P.E.N. clinical guidelines: nutrition support of neonatal patients at risk for necrotizing enterocolitis. JPEN J Parenter Enteral Nutr (2012) 3.42
Associations between HIV infection and subclinical coronary atherosclerosis. Ann Intern Med (2014) 3.24
Preclinical atherosclerosis due to HIV infection: carotid intima-medial thickness measurements from the FRAM study. AIDS (2009) 3.12
Adult-onset immunodeficiency in Thailand and Taiwan. N Engl J Med (2012) 2.87
GATA2 deficiency: a protean disorder of hematopoiesis, lymphatics, and immunity. Blood (2013) 2.82
Mortality associated with medical therapy versus elective colectomy in ulcerative colitis: a cohort study. Ann Intern Med (2014) 2.73
Vitamin D deficiency in HIV-infected and HIV-uninfected women in the United States. J Acquir Immune Defic Syndr (2011) 2.65
A simple, dynamic measure of antiretroviral therapy adherence predicts failure to maintain HIV-1 suppression. J Infect Dis (2006) 2.61
Ten-year predicted coronary heart disease risk in HIV-infected men and women. Clin Infect Dis (2007) 2.55
Conceptual framework for understanding the bidirectional links between food insecurity and HIV/AIDS. Am J Clin Nutr (2011) 2.32
Idiopathic CD4+ lymphocytopenia: natural history and prognostic factors. Blood (2008) 2.27
Relationship between alcohol use categories and noninvasive markers of advanced hepatic fibrosis in HIV-infected, chronic hepatitis C virus-infected, and uninfected patients. Clin Infect Dis (2014) 2.24
Long-term effects of finasteride on prostate specific antigen levels: results from the prostate cancer prevention trial. J Urol (2005) 2.24
Bone disease in HIV infection: a practical review and recommendations for HIV care providers. Clin Infect Dis (2010) 2.20
Biomarker-calibrated energy and protein consumption and increased cancer risk among postmenopausal women. Am J Epidemiol (2009) 1.98
Tuberculosis risk factors and mortality for HIV-infected persons receiving antiretroviral therapy in South Africa. AIDS (2010) 1.90
Natural history of autoimmune lymphoproliferative syndrome associated with FAS gene mutations. Blood (2014) 1.88
Short-term bone loss in HIV-infected premenopausal women. J Acquir Immune Defic Syndr (2010) 1.87
Cystatin C, albuminuria, and 5-year all-cause mortality in HIV-infected persons. Am J Kidney Dis (2010) 1.84
Antisense phosphorodiamidate morpholino oligomers targeted to an essential gene inhibit Burkholderia cepacia complex. J Infect Dis (2010) 1.84
Immunosuppressant medications and mortality in inflammatory bowel disease. Am J Gastroenterol (2008) 1.80
Inhaled amikacin for treatment of refractory pulmonary nontuberculous mycobacterial disease. Ann Am Thorac Soc (2014) 1.76
Accurate determination of energy needs in hospitalized patients. J Am Diet Assoc (2007) 1.69
Association of HIV infection, demographic and cardiovascular risk factors with all-cause mortality in the recent HAART era. J Acquir Immune Defic Syndr (2010) 1.67
Association of serum lipid levels with HIV serostatus, specific antiretroviral agents, and treatment regimens. J Acquir Immune Defic Syndr (2007) 1.66
Cancer incidence in The Health Improvement Network. Pharmacoepidemiol Drug Saf (2009) 1.65
Hepatic decompensation in antiretroviral-treated patients co-infected with HIV and hepatitis C virus compared with hepatitis C virus-monoinfected patients: a cohort study. Ann Intern Med (2014) 1.64
The parametric g-formula to estimate the effect of highly active antiretroviral therapy on incident AIDS or death. Stat Med (2012) 1.63
Non-viral causes of hepatocellular carcinoma. World J Gastroenterol (2010) 1.63
Validity of The Health Improvement Network (THIN) for epidemiologic studies of hepatitis C virus infection. Pharmacoepidemiol Drug Saf (2009) 1.61
Prevalence and predictors of Toxoplasma seropositivity in women with and at risk for human immunodeficiency virus infection. Clin Infect Dis (2002) 1.59
Association of HIV and ART with cardiometabolic traits in sub-Saharan Africa: a systematic review and meta-analysis. Int J Epidemiol (2013) 1.57
Vitamin D deficiency is associated with type 2 diabetes mellitus in HIV infection. AIDS (2011) 1.55
Incidence and risk factors for steatosis progression in adults coinfected with HIV and hepatitis C virus. Gastroenterology (2010) 1.53
Out-of-pocket costs of HAART limit HIV treatment responses in Botswana's private sector. AIDS (2006) 1.51
Frailty, HIV infection, and mortality in an aging cohort of injection drug users. PLoS One (2013) 1.46
A.S.P.E.N. clinical guidelines: Nutrition screening, assessment, and intervention in adults. JPEN J Parenter Enteral Nutr (2011) 1.46
Treatment-related changes in serum lipids and inflammation: clinical relevance remains unclear. Analyses from the Women's Interagency HIV study. AIDS (2013) 1.43
Activation of CD8 T cells predicts progression of HIV infection in women coinfected with hepatitis C virus. J Infect Dis (2010) 1.42
A.S.P.E.N. Clinical Guidelines: hyperglycemia and hypoglycemia in the neonate receiving parenteral nutrition. JPEN J Parenter Enteral Nutr (2011) 1.41
Histologic predictors of fibrosis progression in liver allografts in patients with hepatitis C virus infection. Clin Gastroenterol Hepatol (2009) 1.41
Vitamin D deficiency and persistent proteinuria among HIV-infected and uninfected injection drug users. AIDS (2012) 1.41
A case of Cronkhite-Canada syndrome with taste disturbance as a leading complaint. Digestion (2005) 1.41
Xenodiagnosis to detect Borrelia burgdorferi infection: a first-in-human study. Clin Infect Dis (2014) 1.39
Microalbuminuria is associated with all-cause and AIDS mortality in women with HIV infection. J Acquir Immune Defic Syndr (2010) 1.37
Potential cardiovascular disease risk markers among HIV-infected women initiating antiretroviral treatment. J Acquir Immune Defic Syndr (2012) 1.37
Time scale and adjusted survival curves for marginal structural cox models. Am J Epidemiol (2010) 1.36
Inflammation markers after randomization to abacavir/lamivudine or tenofovir/emtricitabine with efavirenz or atazanavir/ritonavir. AIDS (2012) 1.34
Regional adipose tissue and lipid and lipoprotein levels in HIV-infected women. J Acquir Immune Defic Syndr (2008) 1.34
A.S.P.E.N. Clinical Guidelines: nutrition support of the critically ill child. JPEN J Parenter Enteral Nutr (2009) 1.33
Prevalence and risk factors for significant liver fibrosis among HIV-monoinfected patients. BMC Infect Dis (2010) 1.33
The Yale cTAKES extensions for document classification: architecture and application. J Am Med Inform Assoc (2011) 1.33
Clinical presentation and course of acute hepatitis C infection in HIV-infected patients. J Acquir Immune Defic Syndr (2006) 1.32
Macrophage inflammatory markers are associated with subclinical carotid artery disease in women with human immunodeficiency virus or hepatitis C virus infection. Arterioscler Thromb Vasc Biol (2014) 1.32
Obesity and immune cell counts in women. Metabolism (2007) 1.31
Regional adipose tissue measured by MRI over 5 years in HIV-infected and control participants indicates persistence of HIV-associated lipoatrophy. AIDS (2010) 1.29
Adult starvation and disease-related malnutrition: a proposal for etiology-based diagnosis in the clinical practice setting from the International Consensus Guideline Committee. JPEN J Parenter Enteral Nutr (2010) 1.27
Illicit drug use and HIV treatment outcomes in a US cohort. AIDS (2008) 1.24
Validation of three coding algorithms to identify patients with end-stage liver disease in an administrative database. Pharmacoepidemiol Drug Saf (2012) 1.24
Low baseline CD4+ count is associated with greater bone mineral density loss after antiretroviral therapy initiation. Clin Infect Dis (2013) 1.23
Ultrasonographic measures of cardiovascular disease risk in antiretroviral treatment-naive individuals with HIV infection. AIDS (2013) 1.23
Validity of diagnostic codes to identify cases of severe acute liver injury in the US Food and Drug Administration's Mini-Sentinel Distributed Database. Pharmacoepidemiol Drug Saf (2013) 1.23
Pain and physical and psychological symptoms in ambulatory HIV patients in the current treatment era. J Pain Symptom Manage (2011) 1.23
Bone loss in the HIV-infected patient: evidence, clinical implications, and treatment strategies. J Infect Dis (2012) 1.22
Assessing mortality in women with hepatitis C virus and HIV using indirect markers of fibrosis. AIDS (2012) 1.21
Circulating monocytes in HIV-1-infected viremic subjects exhibit an antiapoptosis gene signature and virus- and host-mediated apoptosis resistance. J Immunol (2009) 1.20
Thyroid function abnormalities in HIV-infected patients. Clin Infect Dis (2007) 1.20
Decreased limb muscle and increased central adiposity are associated with 5-year all-cause mortality in HIV infection. AIDS (2011) 1.19
Fracture incidence in HIV-infected women: results from the Women's Interagency HIV Study. AIDS (2010) 1.19
Sex hormones, insulin resistance, and diabetes mellitus among men with or at risk for HIV infection. J Acquir Immune Defic Syndr (2011) 1.17
Prevalence and correlates of elevated body mass index among HIV-positive and HIV-negative women in the Women's Interagency HIV Study. AIDS Patient Care STDS (2009) 1.17
Connections between survey calibration estimators and semiparametric models for incomplete data. Int Stat Rev (2011) 1.17
Factors associated with hepatitis C viremia in a large cohort of HIV-infected and -uninfected women. J Clin Virol (2008) 1.15
The impact of kidney function at highly active antiretroviral therapy initiation on mortality in HIV-infected women. J Acquir Immune Defic Syndr (2010) 1.15
Vitamin D supplementation and endothelial function in vitamin D deficient HIV-infected patients: a randomized placebo-controlled trial. Antivir Ther (2011) 1.14
Guidelines for the Provision and Assessment of Nutrition Support Therapy in the Adult Critically Ill Patient: Society of Critical Care Medicine (SCCM) and American Society for Parenteral and Enteral Nutrition (A.S.P.E.N.). Crit Care Med (2016) 1.14
Regional fat deposition and cardiovascular risk in HIV infection: the FRAM study. AIDS Care (2011) 1.13
The association of bone mineral density with HIV infection and antiretroviral treatment in women. Antivir Ther (2007) 1.13
Baseline viral load and immune activation determine the extent of reconstitution of innate immune effectors in HIV-1-infected subjects undergoing antiretroviral treatment. J Immunol (2007) 1.12
Effect of highly active antiretroviral therapy on incident AIDS using calendar period as an instrumental variable. Am J Epidemiol (2009) 1.09
Association of low level viremia with inflammation and mortality in HIV-infected adults. PLoS One (2011) 1.09
Factors associated with seronegative chronic hepatitis C virus infection in HIV infection. Clin Infect Dis (2007) 1.09
Inability of plasmacytoid dendritic cells to directly lyse HIV-infected autologous CD4+ T cells despite induction of tumor necrosis factor-related apoptosis-inducing ligand. J Virol (2009) 1.08
Free testosterone for hypogonadism assessment in HIV-infected men. Clin Infect Dis (2014) 1.07
Associations of inflammatory markers with AIDS and non-AIDS clinical events after initiation of antiretroviral therapy: AIDS clinical trials group A5224s, a substudy of ACTG A5202. J Acquir Immune Defic Syndr (2014) 1.06
Associations of antiretroviral drug use and HIV-specific risk factors with carotid intima-media thickness. AIDS (2010) 1.06
No increased risk of myocardial infarction among patients with ulcerative colitis or Crohn's disease. Clin Gastroenterol Hepatol (2011) 1.05
A prospective, randomized clinical trial of antiretroviral therapies on carotid wall thickness. AIDS (2015) 1.05
Prediction of resting metabolic rate in critically ill adult patients: results of a systematic review of the evidence. J Am Diet Assoc (2007) 1.04